Apex Medical Corp. (4106.TW)
TWD 20.55
(-8.46%)
TWD 20.55
(-8.46%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -283.82 Million TWD | -796.99% |
| 2022 | 40.72 Million TWD | -22.9% |
| 2021 | 52.81 Million TWD | 236.41% |
| 2020 | -38.71 Million TWD | -116.57% |
| 2019 | 233.67 Million TWD | -6.41% |
| 2018 | 249.67 Million TWD | 53.94% |
| 2017 | 162.18 Million TWD | -8.18% |
| 2016 | 176.63 Million TWD | 710.83% |
| 2015 | 21.78 Million TWD | 113.16% |
| 2014 | -165.59 Million TWD | -235.71% |
| 2013 | -49.32 Million TWD | 76.22% |
| 2012 | -207.46 Million TWD | 40.38% |
| 2011 | -347.97 Million TWD | -15.77% |
| 2010 | -300.57 Million TWD | -21.33% |
| 2009 | -247.73 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -195.91 Million TWD | 30.97% |
| 2024 Q2 | -299.25 Million TWD | -52.75% |
| 2023 Q3 | -161.47 Million TWD | -190.8% |
| 2023 Q1 | -31.95 Million TWD | -178.46% |
| 2023 FY | -283.82 Million TWD | -796.99% |
| 2023 Q4 | -283.82 Million TWD | -75.77% |
| 2023 Q2 | -55.52 Million TWD | -73.79% |
| 2022 Q3 | 169.73 Million TWD | 12.34% |
| 2022 FY | 40.72 Million TWD | -22.9% |
| 2022 Q4 | 40.72 Million TWD | -76.01% |
| 2022 Q1 | 101.05 Million TWD | 91.33% |
| 2022 Q2 | 151.08 Million TWD | 49.51% |
| 2021 FY | 52.81 Million TWD | 236.41% |
| 2021 Q3 | 62.58 Million TWD | 490.76% |
| 2021 Q4 | 52.81 Million TWD | -15.6% |
| 2021 Q1 | -26.92 Million TWD | 30.45% |
| 2021 Q2 | -16.01 Million TWD | 40.52% |
| 2020 Q2 | 65.08 Million TWD | -63.52% |
| 2020 FY | -38.71 Million TWD | -116.57% |
| 2020 Q3 | -31.72 Million TWD | -148.75% |
| 2020 Q4 | -38.71 Million TWD | -22.03% |
| 2020 Q1 | 178.38 Million TWD | -23.66% |
| 2019 Q1 | 386.48 Million TWD | 54.8% |
| 2019 Q3 | 447.87 Million TWD | 6.56% |
| 2019 Q4 | 233.67 Million TWD | -47.82% |
| 2019 FY | 233.67 Million TWD | -6.41% |
| 2019 Q2 | 420.28 Million TWD | 8.74% |
| 2018 Q2 | 145.53 Million TWD | -29.78% |
| 2018 Q3 | 240.62 Million TWD | 65.34% |
| 2018 Q4 | 249.67 Million TWD | 3.76% |
| 2018 Q1 | 207.25 Million TWD | 27.79% |
| 2018 FY | 249.67 Million TWD | 53.94% |
| 2017 Q1 | 227.6 Million TWD | 28.86% |
| 2017 FY | 162.18 Million TWD | -8.18% |
| 2017 Q4 | 162.18 Million TWD | -40.9% |
| 2017 Q3 | 274.41 Million TWD | 5.05% |
| 2017 Q2 | 261.22 Million TWD | 14.77% |
| 2016 Q2 | 135.77 Million TWD | -43.53% |
| 2016 Q3 | 187.95 Million TWD | 38.43% |
| 2016 Q4 | 176.63 Million TWD | -6.02% |
| 2016 Q1 | 240.44 Million TWD | 1003.72% |
| 2016 FY | 176.63 Million TWD | 710.83% |
| 2015 FY | 21.78 Million TWD | 113.16% |
| 2015 Q4 | 21.78 Million TWD | -52.8% |
| 2015 Q3 | 46.15 Million TWD | 118.33% |
| 2015 Q1 | -207.57 Million TWD | -25.35% |
| 2015 Q2 | -251.81 Million TWD | -21.31% |
| 2014 Q2 | -151.43 Million TWD | -97.43% |
| 2014 FY | -165.59 Million TWD | -235.71% |
| 2014 Q1 | -76.69 Million TWD | -55.49% |
| 2014 Q3 | -130.84 Million TWD | 13.6% |
| 2014 Q4 | -165.59 Million TWD | -26.56% |
| 2013 Q1 | -161.36 Million TWD | 22.22% |
| 2013 FY | -49.32 Million TWD | 76.22% |
| 2013 Q4 | -49.32 Million TWD | -75.06% |
| 2013 Q3 | -28.17 Million TWD | 83.1% |
| 2013 Q2 | -166.71 Million TWD | -3.31% |
| 2012 Q1 | -400.84 Million TWD | -15.19% |
| 2012 FY | -207.46 Million TWD | 40.38% |
| 2012 Q4 | -207.46 Million TWD | 0.28% |
| 2012 Q3 | -208.05 Million TWD | 51.89% |
| 2012 Q2 | -432.48 Million TWD | -7.89% |
| 2011 Q2 | -282.96 Million TWD | 2.56% |
| 2011 FY | -347.97 Million TWD | -15.77% |
| 2011 Q1 | -290.4 Million TWD | 3.38% |
| 2011 Q3 | -211.63 Million TWD | 25.21% |
| 2011 Q4 | -347.97 Million TWD | -64.42% |
| 2010 FY | -300.57 Million TWD | -21.33% |
| 2010 Q4 | -300.57 Million TWD | 0.0% |
| 2009 FY | -247.73 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | -1.17 Billion TWD | 75.768% |
| OK Biotech Co., Ltd. | 9.94 Million TWD | 2954.828% |
| Applied BioCode Corporation | -378.76 Million TWD | 25.065% |